Company intelligence / Profile preview

赛岚

Shanghai, Shanghai, Chinasailanbio.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Sailan Bio is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of next-generation epigenetic therapies. The company leverages its proprietary Epigenetic-Targeted Drug Discovery (ETDD) platform to target complex diseases, primarily focusing on oncology and hematological malignancies. Their pipeline includes several small molecule inhibitors, such as CTS2016 and CTS2134, designed to modulate gene expression and overcome drug resistance in cancer. Sailan Bio aims to provide innovative, precision medicines for patients with high unmet medical needs through its deep expertise in epigenetic biology and medicinal chemistry.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 赛岚.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 赛岚.

Explore the full profile